← Back to patent-cliff list
Ardeparin
Tier C — Watch / tradeArdeparin
Wyeth-Ayerst
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SERPINC1, PT, F10
Brand：Normiflo
Indications (approved)：Pulmonary embolism, Venous thrombosis
Regional status
US
Approved
1997-05-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ardeparin?
Approved indications include: Pulmonary embolism, Venous thrombosis.
When does the Ardeparin patent expire?
No public expiry year is available for Ardeparin yet; this page updates once verified.
How do I get a quote for Ardeparin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27